Objectives/purpose
People affected by haematological malignancies face higher risk of morbidity and mortality from vaccine-preventable infections. However, completion rates of post-treatment immunisations are sub-optimal. Informing service innovation according to the needs and preferences of the target population may improve vaccine uptake. This study aimed to understand barriers, enablers and preferences to vaccination and novel vaccines among this special risk group.
Sample and setting
A two-stage mixed methods study in Australia. A purposive sample of Twenty patients with haematological malignancies who had received treatment within the previous two years participated in interviews. Seventy-eight patients responded to a national, cross-sectional survey.
Procedures
Exploratory semi-structured interviews were conducted and transcribed verbatim. Template analysis was used to develop a coding framework which was then mapped to the COM-B model of behaviour change to identify barriers and enablers. Subsequently, a survey was developed from interview results and disseminated online. Data were analysed using descriptive statistics for quantitative responses and content analysis for open-ended survey responses.
Results
Interviews found that while patients had good understanding of vaccination benefits, substantial barriers existed relating to opportunity (including care coordination, travel, time, and financial costs) and motivation (including concerns regarding intervention fatigue, potential side effects, and vaccine development processes, particularly mRNA technologies). Enablers included personalised information, automated care, and hybrid care models. Survey responses confirmed financial costs were common barriers (34% of respondents), with motivational concerns regarding side effects (53%) and reduced vaccine effectiveness (49%) being common. Patients valued shared care models but considered remaining linked to specialist care crucial.
Conclusion and clinical implications
Novel evidence demonstrates that patients with haematological malignancies face complex barriers to vaccination despite understanding benefits. Findings provide considerations to inform development of more acceptable, accessible, and appropriate vaccination delivery models, particularly hybrid and shared care approaches that maintain specialist oversight while addressing practical barriers.